# A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

> **NCT04109976** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 214 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT04109976
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-13
- **Primary completion:** 2020-11-05
- **Final completion:** 2020-11-13
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2023-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04109976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04109976, "A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04109976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*